# Autem Therapeutics

> Autem Therapeutics is a Hanover, New Hampshire bioelectric oncology company developing AutEMsys, a non-invasive, non-toxic device that delivers personalized, low-level, amplitude-modulated electromagnetic frequencies to patients with solid tumors. Founded by medical oncologist Frederico Costa and led by CEO Michael Choukas, the company targets hepatocellular carcinoma (liver cancer) and other hard-to-treat cancers, aiming to make effective cancer care portable, affordable, and accessible worldwide. Its lead program has earned FDA Breakthrough Device designation for advanced HCC.

- **Founded:** 2017
- **Headquarters:** Hanover, New Hampshire, United States
- **Founders:** Frederico Costa (Co-Founder & Chief Scientific Officer (medical oncologist)), Michael Choukas (Co-Founder & CEO)
- **Team size:** ~15 employees
- **Products:** AutEMsys
- **Notable:** Received FDA Breakthrough Device designation for AutEMsys in advanced hepatocellular carcinoma., Completed initial clinical feasibility studies involving 66 HCC patients with early signals of tumor shrinkage, improved quality of life, and extended survival., Raised $10M Series A-1 in 2022 led by Zentynel Frontier Investments.

## Products & services

- **AutEMsys** — A non-invasive, non-toxic bioelectric therapy system that delivers personalized, low-level, amplitude-modulated electromagnetic (EM) frequencies to patients in two- or four-week intervals. Designed to address dysregulated cancer cell metabolism by restoring electrophysiological balance. A single unit can treat up to 40 patients monthly and requires no refrigeration.

## Achievements

- Received FDA Breakthrough Device designation for AutEMsys in advanced hepatocellular carcinoma.
- Completed initial clinical feasibility studies involving 66 HCC patients with early signals of tumor shrinkage, improved quality of life, and extended survival.
- Raised $10M Series A-1 in 2022 led by Zentynel Frontier Investments.
- Designed a cancer therapy device that needs no refrigeration and can treat up to 40 patients per month.

## Latest updates

- **2022-06** — Closed $10M Series A-1 financing led by Zentynel Frontier Investments and appointed Michael Choukas as CEO.
- **2024-02** — Raised an additional $1.5M to extend the Series A round.
- **2025-06** — Anticipated FDA Investigational Device Exemption (IDE) approvals to begin clinical trials in HCC and glioblastoma in the second half of 2025.

## Links

- Website: https://autemtherapeutics.com
- LinkedIn: https://www.linkedin.com/company/autem-therapeutics

---

Profile page: https://yespress.io/autem-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-16